The clinical research of the Department of Hematology of the LUMC focuses on new developments in allogeneic stem cell transplantation and immunotherapy of hematological diseases, and new treatment strategies in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). For the evaluation and monitoring of new treatment strategies, new innovative methods are developed.
Hendrik Veelken (Head of the Department of Hematology), Fred Falkenburg (Deputy Head of the Department of Hematology), Peter von dem Borne (Chef de Clinique Department of Hematology and Bone Marrow Transplantation), Stijn Halkes (staff member clinical research), and Erik Marijt (Head of the Central Clinical Laboratory Hematology) are responsible for the development of new clinical protocols, implementation of new treatment strategies, and evaluation of the impact of treatment through laboratory research.
The Parelsnoer initiative www.parelsnoer.org the eight University Medical Centers cooperate to come to the construction of a national biobank for leukemia, lymphoma and myeloma. This biobank contains clinical data and collected tumor material and supplies the opportunity to perform national scientific research in the field of pathogenesis and treatment of hematologic malignancies.